Dyadic International, Inc.
140 Intracoastal Pointe Drive
Suite 404
Jupiter
Florida
33477
United States
Tel: 561-743-8333
Fax: 561-743-8343
Website: http://www.dyadic-group.com/
Email: memalfarb@dyadic-group.com
255 articles about Dyadic International, Inc.
-
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
3/14/2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.
-
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
3/11/2024
Dyadic International, Inc. announced today that it entered into a securities purchase agreement on March 8, 2024, pursuant to which, the Company has sold and issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027.
-
Dyadic to Attend Industry Events in March 2024
3/1/2024
Dyadic International, Inc. announced that its management will be attending the following industry events during the month of March 2024.
-
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
2/28/2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV (“Rabian”), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists.
-
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
2/21/2024
Dyadic International, Inc. announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel.
-
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
2/13/2024
Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila).
-
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
2/6/2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform.
-
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
2/1/2024
Dyadic International, Inc. today announced that its management will be attending the following events during the month of February 2024.
-
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
1/2/2024
Dyadic International, Inc. today announced that its management will be attending the following events during the J.P. Morgan 42nd Annual Healthcare Conference in January 2024.
-
Dyadic Attends Investor Events in December 2023
11/30/2023
Dyadic International, Inc. announced that its management will be attending the following investor events during the month of December:
-
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
11/29/2023
Dyadic International, Inc. today announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100.
-
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
11/8/2023
Dyadic International, Inc. announced its financial results for the third quarter of 2023, and highlighted recent company developments.
-
Dyadic to Present at Industry Events in November
10/30/2023
Dyadic International, Inc. today announced that its management will be participating and presenting at the following industry events during the month of November.
-
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
10/25/2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.
-
Dyadic Appoints Doug Pace to Its Executive Leadership Team
10/9/2023
Dyadic International, Inc. announced the appointment of Doug Pace as Executive Vice President of Business Development.
-
Dyadic’s C1 Platform Selected by the VIC at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a SAV Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
10/5/2023
Dyadic International, Inc. announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc., to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.
-
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
9/26/2023
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA ("mRNA").
-
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
9/19/2023
Dyadic International, Inc today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.
-
Dyadic to Present at BioProcess International
9/12/2023
Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
-
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
8/9/2023
Dyadic International, Inc. announced its financial results for the second quarter of 2023, and highlighted recent company developments.